Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00851721 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor
A Phase 3 study, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT00851721 is a Phase 3 study that has completed, run by Baxalta now part of Shire. The registered enrollment target is 52 participants.
The verdict
NCT00851721, a Phase 3 study, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of the study was to determine the efficacy, safety, and health-related quality of life benefits with FEIBA NF prophylactic treatment as compared with on-demand treatment.
Interventions
- BIOLOGICAL Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2009-03-31 |
| Est. Completion | 2012-10-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00851721
The ClinicalTrials.gov registry entry for NCT00851721 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) is the first listed.
NCT00851721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00851721 about?
NCT00851721 is a clinical study titled "Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor". The purpose of the study was to determine the efficacy, safety, and health-related quality of life benefits with FEIBA NF prophylactic treatment as compared with on-demand treatment.
What is the current status of trial NCT00851721?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2009-03-31. Estimated completion is 2012-10-17.
What interventions are being tested in trial NCT00851721?
The interventions under investigation include: Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00851721?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.